Clinical Trials Logo

Barrett Adenocarcinoma clinical trials

View clinical trials related to Barrett Adenocarcinoma.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05276791 Not yet recruiting - Esophageal Cancer Clinical Trials

EMR Versus ESD for Barrett's Neoplasia

REMOVE-RCT
Start date: December 1, 2022
Phase: N/A
Study type: Interventional

Rationale: The optimal technique for removal of visible dysplastic lesions in Barrett's esophagus remains controversial. Endoscopic mucosal resection (EMR) is safe, effective, easy to apply, and has been the most widely used technique since 2008. Endoscopic submucosal dissection (ESD) is a more controlled dissection method with potential improved efficacy, but at the cost of higher technical complexity. Objective: The investigators aim to compare EMR and ESD for removal of visible lesions in Barrett's esophagus. Study design: Randomized clinical trial Study population: Patients with Barrett's esophagus and a visible lesion with dysplasia and/or early cancer. Suspicion for submucosal invasion is an exclusion criterion. Intervention: Patients are randomized to receive either EMR or ESD, with follow-up and no ablation during 12 months after the resection. Main study endpoint: Primary endpoint is the proportion of patients with no evidence of residual or local recurrent neoplasia during 12 months follow-up after baseline.